Artikel
Characteristics and outcomes of SARS-CoV-2 breakthrough infections among double-vaccinated and triple-vaccinated patients with inflammatory rheumatic diseases
Suche in Medline nach
Autoren
-
Rebecca Hasseli-Fräbel
- Department of Internal Medicine D, Section of Rheumatology and Clinical Immunology, University Hospital Munster, Germany; Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Germany
-
Jutta G. Richter
- Clinic for Rheumatology, University Hospital Duesseldorf, Medical Faculty of Heinrich-Heine-University Duesseldorf, Germany; Hiller Research Center, University Hospital Duesseldorf, Medical Faculty of Heinrich-Heine-University Duesseldorf, Germany
-
Bimba Franziska Hoyer
- Clinic for Internal Medicine I, Rheumatology and Clinical Immunology, University Medical Center Schleswig-Holstein Campus, Kiel, Germany
-
Hanns-Martin Lorenz
- Division of Rheumatology, Department of Medicine V, University Hospital Heidelberg, Germany
-
Alexander Pfeil
- Department of Internal Medicine III, University Hospital Jena, Germany
-
Anne Constanze Regierer
- Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany
-
Tim Schmeiser
- Rheumatology, Private Practice “Rheumatologie im Veedel” Cologne, Germany
-
Anja Strangfeld
- Epidemiology Unit, German Rheumatism Research Centre, Berlin, Germany; Department of Rheumatology and Clinical Immunology, Charité Universitätsmedizin, Berlin, Germany
-
Reinhard E Voll
- Department of Rheumatology and Clinical Immunology, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany; Centre of Chronic Immunodeficiency, Medical Center – University of Freiburg, Faculty of Medicine, Freiburg, Germany
-
Andreas Krause
- Department of Rheumatology, Clinical Immunology and Osteology, Immanuel Hospital, Berlin, Germany
-
Sabine Reckert
- Rheumatology, Private Practice, Potsdam, Germany
-
Anett Gräßler
- Rheumatology, Private Practice, Pirna, Germany
-
Petra Saar
- Rheumatology, Private Practice Endokrinologikum, Frankfurt, Germany
-
Andreas Kapelle
- Rheumatology, Private Practice, Hoyerswerda, Germany
-
Marina Backhaus
- Department of Internal Medicine, Rheumatology and Clinical Immunology, Park-Klinik Weissensee, Academic Hospital of the Charité Berlin, Germany
-
Norbert Blank
- Division of Rheumatology, Department of Medicine V, University Hospital Heidelberg, Germany
-
Joerg Henes
- Centre for Interdisciplinary Clinical Immunology, Rheumatology and Autoinflammatory Diseases (INDIRA) and Department of Internal Medicine II (Oncology, Haematology, Rheumatology and Clinical Immunology), University Hospital Tuebingen, Germany
-
Silke Osiek
- Rheumatology, Private Practice Dialysezentrum, Schweinfurt, Germany
-
Anna Knothe
- Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Germany
-
Guido Hoese
- Rheumatology, Private Practice, Stadthagen, Germany
-
Jan Brandt-Jürgens
- Rheumatology, Private Practice, Berlin, Germany
-
Anja Maltzahn
- Rheumatology, Private Practice, Göttingen, Germany
-
Christof Specker
- Department of Rheumatology and Clinical Immunology, KEM Kliniken Essen-Mitte, Essen, Germany
-
Ulf Müller-Ladner
- Department of Rheumatology and Clinical Immunology, Campus Kerckhoff, Justus Liebig University Giessen, Germany
-
Hendrik Schulze-Koops
- Division of Rheumatology and Clinical Immunology, Department of Internal Medicine IV, Ludwig-Maximilians-University, Munich, Germany
| Veröffentlicht: | 10. September 2024 |
|---|
Gliederung
Text
Objective: To analyse the clinical profile of SARS-CoV-2 breakthrough infections in at least double-vaccinated patients with inflammatory rheumatic diseases (IRDs).
Methods: Data from the physician-reported German COVID-19-IRD registry collected between February 2021 and July 2022 were analysed. SARS-CoV-2 cases were stratified according to patients’ vaccination status as being not vaccinated, double-vaccinated or triple-vaccinated prior to SARS-CoV-2 infection and descriptively compared. Independent associations between demographic and disease features and outcome of breakthrough infections were estimated by multivariable logistic regression.
Results: In total, 2,314 cases were included in the analysis (unvaccinated n=923, double-vaccinated n=551, triple-vaccinated n=803, quadruple-vaccinated n=37). SARS-CoV-2 infections occurred after a median of 151 (range 14–347) days in patients being double-vaccinated, and after 88 (range 14–270) days in those with a third vaccination. Hospitalisation was required in 15% of unvaccinated, 8% of double-vaccinated and 3% of triple-vaccinated/quadruple-vaccinated patients (p<0.001). Mortality was 2% in unvaccinated, 1.8% in the double-vaccinated and 0.6% in triple-vaccinated patients. Compared with unvaccinated patients, double-vaccinated (OR 0.43, 95% CI 0.29 to 0.62) and triple-vaccinated (OR 0.13, 95% CI 0.08 to 0.21) patients showed a significant lower risk of COVID-19-related hospitalisation. Using multivariable analysis, the third vaccination was significantly associated with a lower risk for COVID-19-related death (OR 0.26; 95% CI 0.01 to 0.73).
Conclusions: Our cross-sectional data of COVID-19 infections in patients with IRD showed a significant reduction of hospitalisation due to infection in double-vaccinated or triple-vaccinated patients compared with those without vaccination and even a significant reduction of COVID-19-related deaths in triple-vaccinated patients. These data strongly support the beneficial effect of COVID-19 vaccination in patients with IRD.
Trial registration number EuDRACT 2020-001958-21.
